# Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus

> **NCT02761629** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 180 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Peg-Interferon Alpha-2A
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02761629
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2016-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02761629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02761629, "Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02761629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*